Biopharmaceutical News and Research

RSS

Halozyme Therapeutics secures multiple commercial supply agreements for rHuPH20

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the execution of multiple commercial supply agreements with its existing manufacturing partners. Halozyme amended an existing commercial supply agreement with Avid Bioservices, Inc., entered into a new commercial supply agreement with Avid and entered into a new commercial supply agreement with Cook Pharmica LLC.

5 Apr 2010

Selecta Biosciences raises $15M in new Series C financing round

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.

5 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

Kyto Biopharma enters agreement with Targeted Payload Therapeutics

Kyto Biopharma Inc., is a Florida biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

3 Apr 2010

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Eli Lilly and Company today announced that the U.S. District Court for the Southern District of Indiana has upheld the validity of the company's compound patent on Gemzar® (gemcitabine HCl for injection). This decision maintains Lilly's U.S. exclusivity for Gemzar through November 15, 2010.

2 Apr 2010

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Santarus, Inc., a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc., the consumer healthcare subsidiary of Merck & Co., Inc., has commenced promotion of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its licensing agreement with Santarus for the over-the-counter (OTC) market in North America. The OTC heartburn market in the U.S. is estimated at approximately $1.8 billion based on data from market research firm Information Resources, Inc. and Santarus estimates.

2 Apr 2010

Ricerca Biosciences, Life Science Partner announce business development agreement

Ricerca Biosciences, a preclinical contract research drug development company, is pleased to announce a business development agreement with Life Science Partner (LSP) Co., Ltd., of Tokyo, Japan. Ricerca offers a unique spectrum of services for the areas of agrochemical registration, environmental analysis and pre-investigational new drug (IND) biopharmaceutical registration.

1 Apr 2010

ARCA biopharma raises $6.8M through sale of 1,075,000 common stock shares

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that during the first quarter of 2010, through its previously established equity distribution agreement, it raised net proceeds of approximately $6.8 million through the sale of 1,075,000 shares of ARCA common stock in open market.

1 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

GeoVax Labs files registration statement for offering to sell up to $40.0 million of units

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities Commission for a best efforts offering to sell up to $40.0 million of units consisting of one share of common stock and a warrant to purchase 0.20 shares of common stock. The offering anticipates including shares of common stock to be sold by selling stockholders.

1 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

Investment report on ADVENTRX Pharmaceuticals

BeaconEquity.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

1 Apr 2010

Underwriters exercise over-allotment option to purchase additional 968,539 shares of AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of common stock have exercised their option to purchase an additional 968,539 shares of common stock to cover over-allotments.

1 Apr 2010

BeaconEquity.com announces investment report featuring OXiGENE

BeaconEquity.com announces an investment report featuring OXiGENE Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

Investment report on Sunesis Pharmaceuticals

StockPreacher.com announces an investment report featuring Sunesis Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for the use of menadione to prevent and treat skin rash in patients taking biologic and small molecule epidermal growth factor receptor inhibitors, such as Erbitux® and Tarceva®, for anti-cancer therapy.

31 Mar 2010

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.

30 Mar 2010

Biopharmaceutical News and Research

Halozyme Therapeutics secures multiple commercial supply agreements for rHuPH20

Selecta Biosciences raises $15M in new Series C financing round

Clinical utility and pharmacological action of MN-166 in treatment of MS

Kyto Biopharma enters agreement with Targeted Payload Therapeutics

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Ricerca Biosciences, Life Science Partner announce business development agreement

ARCA biopharma raises $6.8M through sale of 1,075,000 common stock shares

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

GeoVax Labs files registration statement for offering to sell up to $40.0 million of units

Soligenix's revenues for 2009 increase by 22%

Investment report on ADVENTRX Pharmaceuticals

Underwriters exercise over-allotment option to purchase additional 968,539 shares of AVEO Pharmaceuticals

BeaconEquity.com announces investment report featuring OXiGENE

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

Investment report on Sunesis Pharmaceuticals

PhRMA report: 234 medicines in development for special health care needs of children

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Event guide: 3rd EHS for Biopharma Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News